Clinics in Dermatology
Volume 26, Issue 5 , Pages 424-431 , September 2008

Economic considerations in psoriasis management

  • Marc Alexander Radtke, MD
    • ,
  • Matthias Augustin, MD

      Affiliations

    • Corresponding Author InformationCorresponding author. Center for Dermatological Research (CeDeF), Health Economics and QoL Research Group, German Center for Health Services Research in Dermatology (CVderm), Department of Dermatology, University Clinics of Hamburg, 20246 Hamburg, Germany. Tel.: +49 40 42803 5428; fax: +49 40 42803 5348.

References 

  1. Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt. 1999;50:715–722
  2. Nijsten T, Meads D, de Korte J, Sampogna F, Gelfand JM, Ongenae K, et al. Cross cultural differences in responses to items of dermatology specific quality of life instruments among psoriasis patients. J Invest Dermatol. 2007;127:2315–2322
  3. Augustin M, Zschocke I. Lebensqualität und Ökonomie bei allergischen Hauterkrankungen. Allergologie, Jahrgang. 2001;24:S. 433–S. 442
  4. Rajagopalan R, Anderson R. Impact of patch testing on dermatology-specific quality of life in patients with allergic contact dermatitis. Am J Contact Dermat. 1997;8:215–221
  5. Linnet J, Jemec GB. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br.J.Dermatol. 1999;140:268–272
  6. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol. 1999;140:667–671
  7. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm.Venereol. 2000;80:430–434
  8. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br.J.Dermatol. 1999;141:1067–1075
  9. Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm.Venereol. 2000;80:272–276
  10. O'Donnell BF, Lawlor FL, Simpson Morgan J. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;133:27
  11. Finlay AY, Kahn GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;9:210–216
  12. Chren MM, Lasker RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin diseases: reliability, validity and responsiveness. J Invest Dermatol. 1996;107:707–713
  13. Zug KA, Littenberg B, Baughman RD, et al. Assessing the preferences of patients with psoriasis. Arch Dermatol. 1995;131:561–568
  14. Rapp SR, Feldman SR, Exum ML, Fleisher AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407
  15. Finzi A, Mantovani L, Belisari A. Italian Association for Studies on Psoriasis. The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. J Eur Acad Dermatol Venereol. 2001;15:320–324
  16. Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology. 2006;212:137–144
  17. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3:511–518
  18. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with wide-spread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139
  19. Rice T. Stichwort Gesundheitsökonomie. Eine kritische Auseinandersetzung. Bonn: KomPart-Verlag; 2004;
  20. Drummond MF, et al. Methods für the economic evaluation of health care Programmers. 3. überarb. Aufl. Oxford: Oxford University Press; 2005;
  21. Beyer F, Zweifel P, Kifmann M. Gesundheitsökonomik. 5. überarb. Berlin, Heidelberg: Auflage Springer; 2005;
  22. Lauterbach K, Schrappe M. Gesundheitsökonomie, Qualitätsmanagement und evidence-based medicine. Eine systematische Einführung. 2. überarb. Stuttgart, New York: Auflage Schattauer; 2003;
  23. Oberender P, Ecker T. Grundelemente der Gesundheitsökonomie. PCO-Verlag Bayreuth; 2001;
  24. Lambert JRMG. Cost-effectiveness of treatments in psoriasis. J Dermatol Treat. 1999;10(Suppl 1):9–13
  25. von der Schulenburg . Ökonomie in der Medizin. Stuttgart: Schattauer-Verlag; 1996;
  26. Augustin M, Zschocke I, Wenninger K, et al. German adaption of the Skindex-29-Questionnair on quality of life in dermatology: validation and clinical results. Dermatology. 2004;209:14–20
  27. Galdari I, Rigel E, Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol. 2001;15:290–291
  28. De Rie M, de Hoop D, Jönsson L, Bakkers EJM, Sörensen M. Pharmacoeconomic evaluation of calcipotriol and UVB phototherapy in the treatment of psoriasis: a Markov model for the Netherlands. Dermatology. 2001;202:38–43
  29. Javitz H, Ward M, Farber E, Nail L, Valoow S. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850–860
  30. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Current Mediacl Research and Opinion. 2004;12:1929–1936
  31. Cockayne SE, Cork MJ, Gawkrodger D. Treatment of psoriasis: day care vs Inpatient therapy. Br J of Dermatol. 1999;140:375
  32. Koo J. Population based epidemiological study of psoriasis with emphasis on quality of life assessment. Pyschodermatol. 1996;14:485–496
  33. Kurwa HA, Finlay AY. Dermatology inpatient management greatly improves life quality. J Dermatol. 1995;133:575–578
  34. Finlay AY, Coles EC. The effects of severe psoriasis on the quality of life of patients. Br J Dermatol. 1995;132:236–244
  35. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216
  36. Rapp SR, Feldman SR. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?. Dermatol Ther. 2004;17:376–382
  37. Gelfand JM, Feldman SR, TSren RS, et al. Determinants of quality of life in patients with psoriasis: a study from US population. J Am Acad Dermatol. 2004;51:704–708
  38. Zachariae R, Zachariae C, Ibsen HH, et al. Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. Acta Derm Venereol. 2004;84:205–212
  39. Ramsey B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol. 1988;8:95–201
  40. Fried RG. Trivial or terrible? The psychological impact of psoriasis. Int J Dermatol. 1995;34:101–105
  41. Feldman S, Behnam SM, Behnam SE, Koo JY. Involving the patient: impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol. 2005;53(1 Suppl 1):S78–S85
  42. Fortune DG, Richards HL, Kirby B, et al. Psychological stress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol. 2003;139:752–756
  43. Evers AW, Lu Y, Duller P, van der Alk VPG, Kraaimaat FW, van de Kerkhoff PC. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol. 2005;152:1275–1281
  44. Kimball AB, Acobson JC, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–392
  45. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846–850
  46. Ginsberg ICH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989;20:53–63
  47. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001;50:11–15
  48. Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol. 1995;34:700–703
  49. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997;36:259–262
  50. Ryan TJ. Disability in dermatology. Br J Hosp Med. 1991;46:33–36
  51. Schmid-Ott G, Künsebeck HW, Jäger B, et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derma Venereol. 2005;85:27–32
  52. Hornstein OP, Brückner GW, Graf U. Über soziale Bewertung von Hautkrankheiten in der Bevölkerung—Methodik und Ergebnisse einer orientierenden Befragung. Hautarzt. 1973;24:230–235
  53. Schmid-Ott G. Stigmatisierung von Hauterkrankten. In:  Petermann F,  Warschburger P editor. Neurodermitis. Göttingen: Hofgrefe; 1999;p. S 157–S 174
  54. Koblenzer CS. The emotional impact of chronic and disabling skin disease: a psychoanalytic perspective. Dermatol Clin. 2005;23:619–627
  55. Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern R. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol. 2006;[adv. online publication]
  56. Skevington SM, Bradshaw A, Hepplewhite A, Dawkes K, Lovell CR. How does psoriasis affect quality of life? Assessing an Ingram-regimen outpatient programme and validating the WHOQOL-100. B J Dermaol. 2006;154:680–691
  57. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17:24–28
  58. Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D. Italian multipurpose psoriasis research on vital experiences (improve) study group. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol. 2006;154:325–331
  59. Uttjek M, Dufaker M, Nygren L, Stenberg B. Psoriasis care consumption and expectations from a gender perspective in a psoriasis population in northern Sweden. Acta Derm Venereol. 2005;85:503–508
  60. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6
  61. Jankowiak B, Krajeswka-Kulak E, Baranowska A, Krajewska K, Rolka H, Sierakowska M, et al. The importance of the health education in life quality improvement in patients with psoriasis. Rocz Akad Med Bialymst. 2005;50(Suppl 1):145–147
  62. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol. 2005;152:1256–1262
  63. Young M. The psychological and social burden of psoriasis. Dermatol Nurs. 2005;17:15–19
  64. Feldman SR, Clark AR, Venkat AP, FleischerJr AB, Anderson RT, Rajagopalan R. The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol. 2005;152:382–383
  65. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. B J Dermatol. 2005;152:289–295
  66. Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowitz U. Psychological consequences of psoriasis-an empirical study of disease burden in 3753 affected people. Hautarzt. 2005;56:466–472
  67. De Korte J, Van Onselen J, Kownacki S, Sprangers MA, Bos JD. Quality of care in patients with psoriasis: an clinical study of an international disease programme. J Eur Acad Dermatol Venereol. 2005;9:35–41
  68. O'Leary CJ, Creamer D, Higgins E, Weinman J. Perceived stress, stress attributions and psychological distress in psoriasis. J Psychosom Res. 2004;57:465–471
  69. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstand T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–708
  70. Sampogna F, Sera F, Abeni A. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol. 2004;122:602–607
  71. Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. The burden of psoriasis is not determined by disease severity only. J Invest Dermatol Symp Proc. 2004;9:131–135
  72. Uttjek M, Dufaker M, Nygren L, Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol. 2004;84:37–43
  73. Schmidt-Ott G, Burchard R, Niederauer HH, Lamprecht F, Kunsebeck HW. Stigmatization and quality of life of patients with psoriasis and atopic dermatitis. Hautarzt. 2003;54:852–857[Epub 2003 Jul 1]
  74. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512–518
  75. Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol. 2002;16:347–352
  76. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146:1006–1016
  77. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychological impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav. 2000;70:567–571
  78. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35:268–269
  79. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39:447–450
  80. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39:590–596
  81. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol. 1994;31:755–759
  82. Weinstein GD. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol. 1996;135(Suppl 49):32–36
  83. Peeters P, Ortonne JP, Sitbon R, Guignard E. Cost-effectiveness of once-daily treatment with calcipotriol/betamethason dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology. 2005;211:139–145
  84. Krueger G, Koo J, Lebwohl M, Stern R, Rolstad T. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–284
  85. Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. Clin Ther. 1998;20:851–869
  86. Hartman M, Prins M, Swinkels O, Severens J, et al. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol. 2002;147:538–544
  87. Hankin CS, et al. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200–214
  88. Schiffner R, Schiffner-Rohe J, Wölfl G, Landthaler M, Gläβl A, Walther TH, et al. Evaluation of a multicentre study of synchronous application of narrowband ultraviolet B phototherapy (TL-01) and bathing in Dead Sea salt solution for psoriasis vulgaris. Br J Dermatol. 2000;142:740–747
  89. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol. 1993;28:422–425
  90. Chen S, Shaheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckermen therapy for psoriasis. Arch Dermatol. 1998;134:1602–1608
  91. Ellis C, Reiter K, Bandekar R, Fendrick A. Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. J Am Acad Dermatol. 2002;46:242–250
  92. Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat. 2006;17:29–37
  93. Augustin M, Zschocke I, Seidenglanz K, Lange S, Schiffler A, Amon U. Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom. 2000;1:12–17
  94. Augustin M, Amon U, Bullinger M, Gieler U. Recommendations for the assessment of quality of life in dermatology. Dermatol Psychosom. 2000;1:84–87
  95. Augustin M, Radtke M, Moehling U, Peeters P, Lapp C. Cost-effectiveness of psoriasis treatment with a combination of calcipotriol and betamethasone versus monosubstances—economic modeling by Markov method, in print. Dermatology. 2007;

PII: S0738-081X(07)00247-7

doi: 10.1016/j.clindermatol.2007.10.024

Clinics in Dermatology
Volume 26, Issue 5 , Pages 424-431 , September 2008

Article Tools